CEO Statement to Shareholders
Rhea-AI Summary
OSR Holdings (OSRH) addressed Nasdaq minimum-bid timing and reaffirmed portfolio progress on February 2, 2026. Vaximm has a binding term sheet with BCM Europe proposing up to USD 815 million in milestones and USD 30 million upfront (USD 15M cash, USD 15M digital assets).
Separately, management is pursuing a potential merger of device subsidiaries RMC and Woori IO, enabled by recent FDA clarity that supports a dual-track commercialization strategy and growing inbound distributor interest.
Positive
- Potential licensing deal: up to USD 815M in milestones
- Upfront consideration of USD 30M (USD 15M cash, USD 15M digital assets)
- FDA clarity enables dual-track commercialization for Woori IO
- Inbound distributor interest for Woori IO in global markets
- RMC provides an established, cash-flow-generating operating platform
Negative
- VXM01 definitive agreement remains subject to customary conditions and due diligence
- Nasdaq minimum-bid deadline and market volatility may pressure listing status
- Upfront payment includes digital assets, adding execution and valuation uncertainty
News Market Reaction
On the day this news was published, OSRH declined 4.26%, reflecting a moderate negative market reaction. Argus tracked a peak move of +9.8% during that session. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $765K from the company's valuation, bringing the market cap to $17M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows peers like APM down ~6% and TRAW down ~9.48%, while OSRH’s setup reflects company-specific pressures tied to Nasdaq bid compliance rather than a clear sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Subsidiary acquisition | Positive | -3.9% | Completed Woori IO acquisition and launched review of device-subsidiary combination. |
| Jan 22 | Regulatory/commercial update | Positive | +10.2% | Woori IO highlighted FDA clarification enabling phased wellness and CGM rollout. |
| Jan 16 | Leadership appointment | Positive | -4.4% | Vaximm named a new CSO to advance the VXM platform and VXM01. |
| Jan 12 | Licensing term sheet | Positive | +8.3% | Vaximm signed binding term sheet for global VXM01 license with BCM Europe. |
| Dec 19 | Share exchange approval | Positive | +13.7% | Woori IO shareholders approved share exchange to become OSR Holdings subsidiary. |
Recent news has been mostly positive strategically, but price reactions have been mixed, with several constructive developments followed by either modest gains or short-term pullbacks.
Over the past few months, OSR Holdings reported multiple strategic steps across its biotech and medical-device portfolio. Vaximm’s VXM01 licensing term sheet with BCM Europe featured a $30M upfront and up to $815M in milestones, while management strengthened Vaximm’s leadership to advance the platform. On the device side, Woori IO’s regulatory and commercialization updates, including FDA clarification on non-medical wearables and completion of its acquisition, underscored OSRH’s dual-track CGM and wellness strategy. The CEO’s latest statement reiterates these themes as Nasdaq minimum bid deadlines approach.
Market Pulse Summary
This announcement reiterates OSR Holdings’ focus on long-term value while navigating Nasdaq bid requirements. The CEO references the VXM01 licensing framework with up to USD 815 million in milestones and a USD 30 million upfront mix of cash and digital assets, alongside a potential merger of RMC and Woori IO and a future Korean listing review. Investors may watch for a definitive VXM01 agreement, formal device-subsidiary merger terms, and clear steps to regain Nasdaq minimum-bid compliance.
Key Terms
continuous glucose monitoring (cgm) medical
AI-generated analysis. Not financial advice.
BELLEVUE, WASHINGTON / ACCESS Newswire / February 2, 2026 / Reaffirming Strategic Execution and Long-Term Value Creation
As the compliance deadline under the minimum bid requirement of NASDAQ approaches, we recognize that market volatility and uncertainty can weigh on investor sentiment. Periods like this often test confidence, particularly for innovation-driven companies that are building long-term value rather than optimizing for short-term optics.
I want to take this opportunity to reaffirm that the fundamentals of OSR Holdings, Inc. remain strong, and that the management team is firmly focused on executing against clearly defined value-creating milestones.
Progress on VXM01 Licensing
Our Swiss biotech subsidiary, Vaximm AG, continues to make solid progress toward finalizing the global licensing transaction for its lead asset, VXM01. Based on the Binding Term Sheet recently executed with BCM Europe AG, the contemplated transaction structure includes:
Up to USD 815 million in development, regulatory, and commercial milestones
USD 30 million upfront consideration, consisting of USD 15 million in cash and USD 15 million in digital assets
While the definitive agreement remains subject to customary conditions, diligence, and final documentation, discussions are advancing constructively and in line with the economic framework already disclosed. We view this potential licensing transaction as a meaningful validation of VXM01's platform value and of OSR Holdings' hub-and-spoke biotech strategy.
Strategic Review of Medical Device Platform Merger
In parallel, we are encouraged by the ongoing strategic discussions between our two medical device subsidiaries, RMC and Woori IO. Management teams from both companies are actively working toward a potential term sheet for a merger of the two entities.
The strategic rationale for this combination has strengthened further in light of recent regulatory clarity from the U.S. Food and Drug Administration regarding the oversight of non-medical-grade consumer wearable devices. This clarification enables Woori IO to pursue a dual-track commercialization strategy:
Consumer wearable products positioned as lifestyle and wellness management tools, which may be commercialized independently of medical-device regulatory approvals
Medical-grade non-invasive continuous glucose monitoring (CGM) devices, which will continue to progress through the appropriate regulatory pathways
As a result of this improved regulatory visibility, Woori IO has recently begun receiving proactive inbound interest from global device distributors, including potential partners prepared to act as importers and local agencies across key international markets. The company aims to announce formal distribution engagements in due course.
When combined with RMC's established, cash-flow-generating operating platform, we believe Woori IO's differentiated technology and expanded commercial optionality create a compelling foundation for growth. Upon consummation of such merger, the combined entity will be evaluated with a view toward a Korean listing, with consideration given to the growth-oriented KOSDAQ market which has recently reached its highest index level in approximately 25 years.
Looking Ahead
OSR Holdings was built to create value through disciplined capital allocation, strategic partnerships, and the maturation of differentiated healthcare technologies. Short-term market dynamics do not change that mission, nor do they alter the intrinsic value we believe is being created across our portfolio.
Management remains fully engaged with regulators, partners, and advisors to address listing requirements in accordance with applicable Nasdaq rules while continuing to advance transactions that we believe can unlock substantial shareholder value. We appreciate the continued support and patience of our investors as we execute on these priorities.
Sincerely,
Kuk Hyoun "Peter" Hwang
Chief Executive Officer
OSR Holdings, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding potential transactions, regulatory pathways, commercialization strategies, anticipated milestones, and future announcements. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update forward-looking statements except as required by law.
About OSR Holdings, Inc.
OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at www.OSR-Holdings.com.
CONTACT:
Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com
SOURCE: OSR Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
What did OSR Holdings (OSRH) announce about the VXM01 licensing on February 2, 2026?
How much upfront consideration does the proposed VXM01 license include for OSR Holdings (OSRH)?
What is the strategic rationale for a potential RMC and Woori IO merger for OSR Holdings (OSRH)?
How does recent FDA guidance affect Woori IO's commercialization strategy under OSR Holdings (OSRH)?
How is OSR Holdings addressing Nasdaq listing requirements amid market volatility on February 2, 2026?
